{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:10:22Z","timestamp":1794067822654,"version":"4.8.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2018-I2M-2-002"],"award-info":[{"award-number":["2018-I2M-2-002"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2018-I2M-2-002"],"award-info":[{"award-number":["2018-I2M-2-002"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Interferon (IFN) signalling pathways, a key element of the innate immune response, contribute to resistance to conventional chemotherapy, radiotherapy, and immunotherapy, and are often deregulated in cancer. The deubiquitylating enzyme USP18 is a major negative regulator of the IFN signalling cascade and is the predominant human protease that cleaves ISG15, a ubiquitin-like protein tightly regulated in the context of innate immunity, from its modified substrate proteins in vivo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, using advanced proteomic techniques, we have significantly expanded the USP18-dependent ISGylome and proteome in a chronic myeloid leukaemia (CML)-derived cell line. USP18-dependent effects were explored further in CML and colorectal carcinoma cellular models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Novel ISGylation targets were characterised that modulate the sensing of innate ligands, antigen presentation and secretion of cytokines. Consequently, CML USP18-deficient cells are more antigenic, driving increased activation of cytotoxic T lymphocytes (CTLs) and are more susceptible to irradiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results provide strong evidence for USP18 in regulating antigenicity and radiosensitivity, highlighting its potential as a cancer target.<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41416-020-01167-y","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T02:03:32Z","timestamp":1605837812000},"page":"817-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity"],"prefix":"10.1038","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1693-9664","authenticated-orcid":false,"given":"Adan","family":"Pinto-Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-3801","authenticated-orcid":false,"given":"Mariolina","family":"Salio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Vere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel Sebastiaan","family":"Olie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Damianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Claire","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Jack","family":"Pegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Chiarenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"D\u00edaz-Saez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gonzalez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Anderton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim R.","family":"Hammonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Muschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Persephone","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cerundolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt M.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"1167_CR1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139\u2013148 (2016).","journal-title":"Eur. J. Cancer"},{"key":"1167_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A. et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Disco. 7, 188\u2013201 (2017).","journal-title":"Cancer Disco."},{"key":"1167_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41586-018-0768-9","volume":"565","author":"JJ Ishizuka","year":"2019","unstructured":"Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K., Panda, A., Iracheta-Vellve, A. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565, 43\u201348 (2019).","journal-title":"Nature"},{"key":"1167_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41591-018-0302-5","volume":"25","author":"H Liu","year":"2019","unstructured":"Liu, H., Golji, J., Brodeur, L. K., Chung, F. S., Chen, J. T., deBeaumont, R. S. et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat. Med. 25, 95\u2013102 (2019).","journal-title":"Nat. Med."},{"key":"1167_CR6","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1073\/pnas.1602069113","volume":"113","author":"S Yoshihama","year":"2016","unstructured":"Yoshihama, S., Roszik, J., Downs, I., Meissner, T. B., Vijayan, S., Chapuy, B. et al. NLRC5\/MHC class I transactivator is a target for immune evasion in cancer. Proc. Natl Acad. Sci. USA 113, 5999\u20136004 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J. P. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","journal-title":"Nat. Commun."},{"key":"1167_CR8","doi-asserted-by":"crossref","unstructured":"Li, K., Qu, S., Chen, X., Wu, Q. & Shi, M. Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways. Int. J. Mol. Sci. 18, 404 (2017).","DOI":"10.3390\/ijms18020404"},{"key":"1167_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00608-2","volume":"8","author":"N Jacquelot","year":"2017","unstructured":"Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternes, N., Jegou, S. et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat. Commun. 8, 592 (2017).","journal-title":"Nat. Commun."},{"key":"1167_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","volume":"20","author":"M McLaughlin","year":"2020","unstructured":"McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A. et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer 20, 203\u2013217 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1167_CR11","doi-asserted-by":"crossref","unstructured":"Havens, C. G., Bjorklund, C., Kang, J., Ortiz, M., Fontanillo, C., Amatangelo, M., et al. IMiDs\u00ae Immunomodulatory agents regulate interferon-stimulated genes through cereblon-mediated aiolos destruction in multiple myeloma (MM) cells: identification of a novel mechanism of action and pathway for resistance. Blood 124, 3432 (2014).","DOI":"10.1182\/blood.V124.21.3432.3432"},{"key":"1167_CR12","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1371\/journal.pone.0000679","volume":"2","author":"A Catic","year":"2007","unstructured":"Catic, A., Fiebiger, E., Korbel, G. A., Blom, D., Galardy, P. J. & Ploegh, H. L. Screen for ISG15-crossreactive deubiquitinases. PLoS ONE 2, e679 (2007).","journal-title":"PLoS ONE"},{"key":"1167_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/embor.2011.17","volume":"12","author":"Y Ye","year":"2011","unstructured":"Ye, Y., Akutsu, M., Reyes-Turcu, F., Enchev, R. I., Wilkinson, K. D. & Komander, D. Polyubiquitin binding and cross-reactivity in the USP domain deubiquitinase USP21. EMBO Rep. 12, 350\u2013357 (2011).","journal-title":"EMBO Rep."},{"key":"1167_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nsmb.3371","volume":"24","author":"A Basters","year":"2017","unstructured":"Basters, A., Geurink, P. P., Rocker, A., Witting, K. F., Tadayon, R., Hess, S. et al. Structural basis of the specificity of USP18 toward ISG15. Nat. Struct. Mol. Biol. 24, 270\u2013278 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1167_CR15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1073\/pnas.1412881112","volume":"112","author":"L Ketscher","year":"2015","unstructured":"Ketscher, L., Hannss, R., Morales, D. J., Basters, A., Guerra, S., Goldmann, T. et al. Selective inactivation of USP18 isopeptidase activity in vivo enhances ISG15 conjugation and viral resistance. Proc. Natl Acad. Sci. USA 112, 1577\u20131582 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR16","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1242\/jcs.205468","volume":"130","author":"C Villarroya-Beltri","year":"2017","unstructured":"Villarroya-Beltri, C., Guerra, S. & Sanchez-Madrid, F. ISGylation\u2014a key to lock the cell gates for preventing the spread of threats. J. Cell Sci. 130, 2961\u20132969 (2017).","journal-title":"J. Cell Sci."},{"key":"1167_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3389\/fchem.2019.00923","volume":"7","author":"D Jimenez Fernandez","year":"2019","unstructured":"Jimenez Fernandez, D., Hess, S. & Knobeloch, K. P. Strategies to target ISG15 and USP18 toward therapeutic applications. Front Chem. 7, 923 (2019).","journal-title":"Front Chem."},{"key":"1167_CR18","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1128\/MCB.00224-09","volume":"29","author":"M Sarasin-Filipowicz","year":"2009","unstructured":"Sarasin-Filipowicz, M., Wang, X., Yan, M., Duong, F. H., Poli, V., Hilton, D. J. et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18\/UBP43. Mol. Cell Biol. 29, 4841\u20134851 (2009).","journal-title":"Mol. Cell Biol."},{"key":"1167_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1101\/gad.1056303","volume":"17","author":"OA Malakhova","year":"2003","unstructured":"Malakhova, O. A., Yan, M., Malakhov, M. P., Yuan, Y., Ritchie, K. J., Kim, K. I. et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 17, 455\u2013460 (2003).","journal-title":"Genes Dev"},{"key":"1167_CR20","doi-asserted-by":"publisher","first-page":"11030","DOI":"10.1128\/MCB.25.24.11030-11034.2005","volume":"25","author":"KP Knobeloch","year":"2005","unstructured":"Knobeloch, K. P., Utermohlen, O., Kisser, A., Prinz, M. & Horak, I. Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of UBP43-deficient mice. Mol. Cell Biol. 25, 11030\u201311034 (2005).","journal-title":"Mol. Cell Biol."},{"key":"1167_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nature13801","volume":"517","author":"X Zhang","year":"2015","unstructured":"Zhang, X., Bogunovic, D., Payelle-Brogard, B., Francois-Newton, V., Speer, S. D., Yuan, C. et al. Human intracellular ISG15 prevents interferon-alpha\/beta over-amplification and auto-inflammation. Nature 517, 89\u201393 (2015).","journal-title":"Nature"},{"key":"1167_CR22","doi-asserted-by":"publisher","first-page":"46424","DOI":"10.1074\/jbc.M403189200","volume":"279","author":"S Tokarz","year":"2004","unstructured":"Tokarz, S., Berset, C., La Rue, J., Friedman, K., Nakayama, K., Nakayama, K. et al. The ISG15 isopeptidase UBP43 is regulated by proteolysis via the SCFSkp2 ubiquitin ligase. J. Biol. Chem. 279, 46424\u201346430 (2004).","journal-title":"J. Biol. Chem."},{"key":"1167_CR23","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1126\/science.1224026","volume":"337","author":"D Bogunovic","year":"2012","unstructured":"Bogunovic, D., Byun, M., Durfee, L. A., Abhyankar, A., Sanal, O., Mansouri, D. et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science 337, 1684\u20131688 (2012).","journal-title":"Science"},{"key":"1167_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09437-x","volume":"10","author":"A Sapmaz","year":"2019","unstructured":"Sapmaz, A., Berlin, I., Bos, E., Wijdeven, R. H., Janssen, H., Konietzny, R. et al. USP32 regulates late endosomal transport and recycling through deubiquitylation of Rab7. Nat. Commun. 10, 1454 (2019).","journal-title":"Nat. Commun."},{"key":"1167_CR25","doi-asserted-by":"publisher","first-page":"e2444","DOI":"10.1038\/cddis.2016.326","volume":"7","author":"N Honke","year":"2016","unstructured":"Honke, N., Shaabani, N., Zhang, D. E., Hardt, C. & Lang, K. S. Multiple functions of USP18. Cell Death Dis. 7, e2444 (2016).","journal-title":"Cell Death Dis."},{"key":"1167_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/0008-5472.CAN-17-1752","volume":"78","author":"LM Mustachio","year":"2018","unstructured":"Mustachio, L. M., Lu, Y., Kawakami, M., Roszik, J., Freemantle, S. J., Liu, X. et al. Evidence for the ISG15-specific deubiquitinase USP18 as an antineoplastic target. Cancer Res. 78, 587\u2013592 (2018).","journal-title":"Cancer Res."},{"key":"1167_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1084\/jem.20151529","volume":"213","author":"ME Meuwissen","year":"2016","unstructured":"Meuwissen, M. E., Schot, R., Buta, S., Oudesluijs, G., Tinschert, S., Speer, S. D. et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J. Exp. Med. 213, 1163\u20131174 (2016).","journal-title":"J. Exp. Med"},{"key":"1167_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/0008-5472.CAN-09-1942","volume":"70","author":"H Potu","year":"2010","unstructured":"Potu, H., Sgorbissa, A. & Brancolini, C. Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. Cancer Res. 70, 655\u2013665 (2010).","journal-title":"Cancer Res."},{"key":"1167_CR29","doi-asserted-by":"publisher","first-page":"77205","DOI":"10.18632\/oncotarget.12858","volume":"7","author":"J Gaston","year":"2016","unstructured":"Gaston, J., Cheradame, L., Yvonnet, V., Deas, O., Poupon, M. F., Judde, J. G. et al. Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents. Oncotarget 7, 77205\u201377224 (2016).","journal-title":"Oncotarget"},{"key":"1167_CR30","doi-asserted-by":"crossref","unstructured":"Radoshevich, L., Impens, F., Ribet, D., Quereda, J. J., Nam Tham, T., Nahori, M. A., et al. ISG15 counteracts Listeria monocytogenes infection. Elife 4, e06848 (2015).","DOI":"10.7554\/eLife.06848"},{"key":"1167_CR31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.bbrc.2005.08.132","volume":"336","author":"NV Giannakopoulos","year":"2005","unstructured":"Giannakopoulos, N. V., Luo, J. K., Papov, V., Zou, W., Lenschow, D. J., Jacobs, B. S. et al. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys. Res. Commun. 336, 496\u2013506 (2005).","journal-title":"Biochem Biophys. Res. Commun."},{"key":"1167_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/978-1-4419-6676-6_18","volume":"54","author":"LA Durfee","year":"2010","unstructured":"Durfee, L. A. & Huibregtse, J. M. Identification and validation of ISG15 target proteins. Subcell. Biochem 54, 228\u2013237 (2010).","journal-title":"Subcell. Biochem"},{"key":"1167_CR33","doi-asserted-by":"publisher","first-page":"10200","DOI":"10.1073\/pnas.0504754102","volume":"102","author":"C Zhao","year":"2005","unstructured":"Zhao, C., Denison, C., Huibregtse, J. M., Gygi, S. & Krug, R. M. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl Acad. Sci. USA 102, 10200\u201310205 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbrc.2006.07.076","volume":"348","author":"T Takeuchi","year":"2006","unstructured":"Takeuchi, T., Inoue, S. & Yokosawa, H. Identification and Herc5-mediated ISGylation of novel target proteins. Biochem Biophys. Res. Commun. 348, 473\u2013477 (2006).","journal-title":"Biochem Biophys. Res. Commun."},{"key":"1167_CR35","doi-asserted-by":"publisher","first-page":"10735","DOI":"10.1073\/pnas.0600397103","volume":"103","author":"JJ Wong","year":"2006","unstructured":"Wong, J. J., Pung, Y. F., Sze, N. S. & Chin, K. C. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc. Natl Acad. Sci. USA 103, 10735\u201310740 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR36","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1038\/onc.2015.474","volume":"35","author":"A Pinto","year":"2016","unstructured":"Pinto, A., Mace, Y., Drouet, F., Bony, E., Boidot, R., Draoui, N. et al. A new ER-specific photosensitizer unravels (1)O2-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT. Oncogene 35, 3976\u20133985 (2016).","journal-title":"Oncogene"},{"key":"1167_CR37","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4049\/jimmunol.167.3.1188","volume":"167","author":"M Salio","year":"2001","unstructured":"Salio, M., Shepherd, D., Dunbar, P. R., Palmowski, M., Murphy, K., Wu, L. et al. Mature dendritic cells prime functionally superior melan-A-specific CD8+ lymphocytes as compared with nonprofessional APC. J. Immunol. 167, 1188\u20131197 (2001).","journal-title":"J. Immunol."},{"key":"1167_CR38","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3389\/fchem.2019.00592","volume":"7","author":"A Pinto-Fernandez","year":"2019","unstructured":"Pinto-Fernandez, A., Davis, S., Schofield, A. B., Scott, H. C., Zhang, P., Salah, E. et al. Comprehensive landscape of active deubiquitinating enzymes profiled by advanced chemoproteomics. Front Chem. 7, 592 (2019).","journal-title":"Front Chem."},{"key":"1167_CR39","doi-asserted-by":"crossref","unstructured":"Davis, S., Charles, P. D., He, L., Mowlds, P., Kessler, B. M. & Fischer, R. Expanding proteome coverage with charge ordered parallel ion analysis (CHOPIN) combined with broad specificity proteolysis. J. Proteome Res. 16, 1288\u20131299 (2017).","DOI":"10.1021\/acs.jproteome.6b00915"},{"key":"1167_CR40","doi-asserted-by":"crossref","unstructured":"Fischer, R. & Kessler, B. M. Gel\u2010aided sample preparation (GASP)\u2014A simplified method for gel\u2010assisted proteomic sample generation from protein extracts and intact cells. PROTEOMICS 15, 1224\u20131229 (2015).","DOI":"10.1002\/pmic.201400436"},{"key":"1167_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nsmb.3378","volume":"24","author":"KI Arimoto","year":"2017","unstructured":"Arimoto, K. I., Lochte, S., Stoner, S. A., Burkart, C., Zhang, Y., Miyauchi, S. et al. STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nat. Struct. Mol. Biol. 24, 279\u2013289 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1167_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13393-x","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y., Thery, F., Wu, N. C., Luhmann, E. K., Dussurget, O., Foecke, M. et al. The in vivo ISGylome links ISG15 to metabolic pathways and autophagy upon Listeria monocytogenes infection. Nat. Commun. 10, 5383 (2019).","journal-title":"Nat. Commun."},{"key":"1167_CR43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","volume":"179","author":"M Harel","year":"2019","unstructured":"Harel, M., Ortenberg, R., Varanasi, S. K., Mangalhara, K. C., Mardamshina, M., Markovits, E. et al. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell 179, 236\u2013250. e18 (2019).","journal-title":"Cell"},{"key":"1167_CR44","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1074\/jbc.M112.401851","volume":"288","author":"F Okumura","year":"2013","unstructured":"Okumura, F., Okumura, A. J., Uematsu, K., Hatakeyama, S., Zhang, D. E. & Kamura, T. Activation of double-stranded RNA-activated protein kinase (PKR) by interferon-stimulated gene 15 (ISG15) modification down-regulates protein translation. J. Biol. Chem. 288, 2839\u20132847 (2013).","journal-title":"J. Biol. Chem."},{"key":"1167_CR45","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/0008-5472.CAN-05-1123","volume":"66","author":"SD Desai","year":"2006","unstructured":"Desai, S. D., Haas, A. L., Wood, L. M., Tsai, Y. C., Pestka, S., Rubin, E. H. et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin\/26S proteasome pathway. Cancer Res 66, 921\u2013928 (2006).","journal-title":"Cancer Res"},{"key":"1167_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07824-4","volume":"9","author":"HS Gannon","year":"2018","unstructured":"Gannon, H. S., Zou, T., Kiessling, M. K., Gao, G. F., Cai, D., Choi, P. S. et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat. Commun. 9, 5450 (2018).","journal-title":"Nat. Commun."},{"key":"1167_CR47","doi-asserted-by":"publisher","first-page":"e0212053","DOI":"10.1371\/journal.pone.0212053","volume":"14","author":"R Mezzadra","year":"2019","unstructured":"Mezzadra, R., de Bruijn, M., Jae, L. T., Gomez-Eerland, R., Duursma, A., Scheeren, F. A. et al. SLFN11 can sensitize tumor cells towards IFN-gamma-mediated T cell killing. PLoS One 14, e0212053 (2019).","journal-title":"PLoS One"},{"key":"1167_CR48","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1182\/blood-2009-02-206557","volume":"113","author":"JR Almeida","year":"2009","unstructured":"Almeida, J. R., Sauce, D., Price, D. A., Papagno, L., Shin, S. Y., Moris, A. et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 113, 6351\u20136360 (2009).","journal-title":"Blood"},{"key":"1167_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25\u201339 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1167_CR50","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1073\/pnas.0813367106","volume":"106","author":"O Talay","year":"2009","unstructured":"Talay, O., Shen, C. H., Chen, L. & Chen, J. B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation. Proc. Natl Acad. Sci. USA 106, 2741\u20132746 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR51","doi-asserted-by":"crossref","unstructured":"Diskin, B., Adam, S., Cassini, M. F., Sanchez, G., Liria, M., Aykut, B., et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat Immunol. 21, 442\u2013454 (2020).","DOI":"10.1038\/s41590-020-0620-x"},{"key":"1167_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05048-0","volume":"9","author":"N Jacquelot","year":"2018","unstructured":"Jacquelot, N., Zitvogel, L. & Eggermont, A. M. Reply to \u2018Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma\u2019. Nat. Commun. 9, 2922 (2018).","journal-title":"Nat. Commun."},{"key":"1167_CR53","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.molcel.2010.05.002","volume":"38","author":"LA Durfee","year":"2010","unstructured":"Durfee, L. A., Lyon, N., Seo, K. & Huibregtse, J. M. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol. Cell 38, 722\u2013732 (2010).","journal-title":"Mol. Cell"},{"key":"1167_CR54","doi-asserted-by":"publisher","unstructured":"Pinto-Fernandez, A., Salio, M., Partridge, T., Chen, J., Vere, G., Greenwood, H. et al. Deep analysis of the USP18-dependent ISGylome and proteome unveils important roles for USP18 in tumour cell antigenicity and radiosensitivity. Preprint at https:\/\/doi.org\/10.1101\/2020.03.31.005629 (2020).","DOI":"10.1101\/2020.03.31.005629"},{"key":"1167_CR55","doi-asserted-by":"publisher","first-page":"D442","DOI":"10.1093\/nar\/gky1106","volume":"47","author":"Y Perez-Riverol","year":"2019","unstructured":"Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res 47, D442\u2013D450 (2019).","journal-title":"Nucleic Acids Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01167-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01167-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01167-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T19:24:26Z","timestamp":1723922666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01167-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2,16]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01167-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HAP1 cells (WT and KO) are a kind gift from the laboratory of Sebastian Nijman and the HCT116 cell line was purchased from ATCC (ATCC-CCL-247).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE<sup>55<\/sup> partner repository with the data set identifier PXD018299.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Work in the BMK lab was funded by FORMA Therapeutics, Pfizer Inc., by an EPSRC grant EP\/N034295\/1 and by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}